ZURAMPIC

Peak

lesinurad

NDAORALTABLET
Approved
Dec 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2

Clinical Trials (2)

NCT04072471N/AWithdrawn

Post-Authorisation Safety Study of Lesinurad

Started Jan 2021
0
GoutHyperuricemia
NCT03226899Phase 4Terminated

A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment

Started Jul 2017

Loss of Exclusivity

LOE Date
Feb 29, 2032
72 months away
Patent Expiry
Feb 29, 2032

Patent Records (5)

Patent #ExpiryTypeUse Code
8283369
Nov 26, 2028
U-1802
10183012
Nov 26, 2028
U-2311
8546437
Apr 29, 2029
U-1803
8084483
Aug 17, 2029
U-1801
8357713
Dec 22, 2029
Product
U-1802